Discovery of Potent Degraders of the Dengue Virus Envelope Protein
Advanced Science · 2024-10 · 11 (40)
DOI: 10.1002/advs.202405829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.08.2024. Verfasst von Zhengnian Li und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford Medicine, Stanford University, 290 Jane Stanford Way, Stan…. Hauptthemen laut MEDLINE: Dengue Virus, Viral Envelope Proteins. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, Mark Foundation For Cancer Research.
Abstract (Originalsprache)
Targeted protein degradation has been widely adopted as a new approach to eliminate both established and previously recalcitrant therapeutic targets. Here, it is reported that the development of small molecule degraders of the envelope (E) protein of dengue virus. Two classes of bivalent E‐degraders are developed by linking two previously reported E‐binding small molecules, GNF‐2, and CVM‐2‐12‐2, to a glutarimide‐based recruiter of the CRL4 CRBN ligase to effect proteosome‐mediated degradation of the E protein. ZXH‐2‐107 (based on GNF‐2) is an E‐degrader with ABL inhibitory activity while ZXH‐8‐004 (based on CVM‐2‐12‐2) is a selective and potent E‐degrader. These two compounds provide proof of concept that difficult‐to‐drug targets such as a viral envelope protein can be effectively eliminated using a bivalent degrader and provide starting points for the future development of a new class of direct‐acting antiviral drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford Medicine, Stanford University, 290 Jane Stanford Way, Stanford, CA, 94305, USA.
- Department of Microbiology and Immunology, Stanford University School of Medicine, 279 Campus Drive, Palo Alto, CA, 94305, USA.
- Department of Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, 02215, USA.
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, 02115, USA.
ORCID-Profile: Nathanael S Gray
Förderung
- NIH National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- Mark Foundation For Cancer Research
- NIGMS NIH HHS
Zitieren
APA
Li, Z., Liu, H. Y., He, Z., Chakravarty, A., Golden, R. P., Jiang, Z., You, I., Yue, H., Donovan, K. A., Du, G., Che, J., Tse, J., Che, I., Lu, W., Fischer, E. S., Zhang, T., Gray, N. S., & Yang, P. L. (2024). Discovery of Potent Degraders of the Dengue Virus Envelope Protein. Advanced Science, 11(40). https://doi.org/10.1002/advs.202405829
Vancouver
Li Z, Liu HY, He Z, Chakravarty A, Golden RP, Jiang Z, et al. Discovery of Potent Degraders of the Dengue Virus Envelope Protein. Advanced Science. 2024;11(40). doi:10.1002/advs.202405829
BibTeX
@article{Li2024,
author = {Li, Zhengnian and Liu, Han-Yuan and He, Zhixiang and Chakravarty, Antara and Golden, Ryan P and Jiang, Zixuan and You, Inchul and Yue, Hong and Donovan, Katherine A and Du, Guangyan and Che, Jianwei and Tse, Jason and Che, Isaac and Lu, Wenchao and Fischer, Eric S and Zhang, Tinghu and Gray, Nathanael S and Yang, Priscilla L},
title = {Discovery of Potent Degraders of the Dengue Virus Envelope Protein},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {40},
doi = {10.1002/advs.202405829}
}
EUVIMED